Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 15, 2022 16:05 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics Announces Appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer

CAMBRIDGE, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced the appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer (CMO). “Kamal...
September 07, 2022 08:05 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics to Present at Upcoming Investor Conference

CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
September 06, 2022 08:05 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration

Alignment with the FDA on a regulatory path forward for the continued development of tebipenem Hbr FDA feedback indicates positive results from a single additional Phase 3 clinical trial in patients...
August 10, 2022 16:05 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics Announces Second Quarter 2022 Operating Results and Provides Business Update

Initiation of a Placebo-controlled Phase 2 Trial of SPR720 in Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) Expected in 4Q 2022 Initiation of a Phase 2 Cross-indication Resistant Pathogen...
August 09, 2022 08:05 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022

CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Wednesday, August 10, 2022...
June 27, 2022 16:05 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Tebipenem HBr New Drug Application

CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug...
May 16, 2022 16:05 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics Announces First Quarter 2022 Operating Results and Provides Business Update

New Strategic Direction Focuses on Advancing the Clinical Stage Pipeline and Identifying Tebipenem’s Optimal Path to Value Creation Initiation of a Phase 2 Trial of SPR720 in Nontuberculous...
May 11, 2022 08:05 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., May 11, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
May 09, 2022 08:05 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results on Monday, May 16, 2022

CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Monday, May 16, 2022, at 4:30...
May 03, 2022 07:05 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics Announces New Strategic Direction Focusing on Advancing Promising Clinical-Stage Pipeline

Announces Immediate Cessation of Tebipenem HBr Commercialization Initiatives; Company to Shift Focus to Advancement of SPR720 and SPR206 Spero to Explore Strategic Partnerships and Other...